Enveric Biosciences, Inc.

ENVB

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0000890821


None

No letter

4 of 13 inputs computable; 7 are required, with a score in every sleeve


Scoreboard	
Reliability	0.76 AUC filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	under $12.5M assets total assets $5.1M
Standard universe	outside revenue above $1M and assets above $10M
Warnings	dilution, thin data; fortress balance sh... not computable: short runway, distress
Inputs computable	4 of 13
Graded from	filings received through Mar 27, 2026 238 days before the rescan; latest periodic filing 10-Q received Nov 13, 2026
Last close	$1.41 2026-11-19; market equity $6.3M; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Mar 27, 2026

the laws of the State of Delaware in February 1994 as Spatializer Audio Laboratories, Inc., which was a shell company immediately prior to the completion of a "reverse merger" transaction on May 26, 2015, whereby Ameri100 Acquisition, Inc., a Delaware corporation and newly created, wholly owned subsidiary, was merged with and into Ameri and Partners Inc. ("Ameri and Partners"), a Delaware corporation (the "2015 Merger"). In connection with the 2015 Merger, we changed our name to AMERI Holdings, Inc. to be part of the Company on December 30, 2020, pursuant to a spin-off transaction.

The thirteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 27.3						
Gross profitability	not computable	32.8%				
latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31						
Return on invested capital	not computable	9.6%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Accruals ratio	(15.4%)	(6.7%)		27.3	756	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 4						
Solvency, sleeve percentile 34.6						
Altman Z double-prime	not computable	0.31				
latest aligned inputs end 2022-12-31; latest annual assets end 2025-12-31						
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(3.61x)				
interest expense must exceed $100,000						
Current ratio	5.38x	2.68x		34.6	781	2025-12-31
Growth and financing, sleeve percentile 95.7						
Revenue growth, three-year compound	not computable	9.6%				
latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31						
Free cash flow growth, three-year compound	not computable	11.1%				
four consecutive annual FCF observations are required; found 2						
Reinvestment rate	not computable	33.9%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	(36.1%)	3.2%		95.5	663	2025-12-31
Net share issuance, one year	816.4%	1.6%		95.8	625	2026-03-24

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Dilution	split-adjusted year-over-year share growth is 816.4%
Thin data	4 of 13 grade factors are computable; minimum is 7
Fortress balance sheet	cash minus debt is 1,364,881 USD; Altman Z is not used

What the price implies

at the 2026-11-19 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(73.9%)	(1.7%)	6
Distance from 52-week high	(86.4%)	(31.7%)	6
EBIT to enterprise value	(252.3%)	0.5%	3
Free cash flow yield	(223.4%)	0.6%	3
Book value to price	0.91	0.29	83
Sales to price	6.32	0.37	98
Composite equity issuance, five years	763.6%	13.5%	99
Relative strength against the sector, log excess return	(1.52)	(0.19)	6
Twelve-month failure probability, CHS model	not computable	0.06%	

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	n/a
Operating cash flow, four quarters	n/a
Months of runway	not finite
Days since last periodic filing	7 (10-Q received Nov 13, 2026)
Median daily dollar volume, 63 sessions	$61,857

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$8.2M	2019-12-31	2020-08-12	10-K/A	20-015385
2	assets	us-gaap:Assets	$108,789	2019-12-31	2021-04-01	10-K	21-007757
3	operating income	us-gaap:OperatingIncomeLoss	-$7.1M	2018-12-31	2020-08-12	10-K/A	20-015385
4	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$10.5M	2018-12-31	2020-08-12	10-K/A	20-015385
5	income tax	us-gaap:IncomeTaxExpenseBenefit	$6.3M	2018-12-31	2020-08-12	10-K/A	20-015385
6	total debt	us-gaap:LongTermDebt	$6,450	2018-12-31	2019-03-26	10-K	19-005573
7	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableT...	$10.8M	2018-12-31	2019-03-26	10-K	19-005573
8	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.4M	2018-12-31	2020-08-12	10-K/A	20-015385
9	total debt	us-gaap:LongTermDebt	$1.9M	2017-12-31	2019-03-26	10-K	19-005573
10	book equity	us-gaap:StockholdersEquityIncludingPortionAttributableT...	$19.4M	2017-12-31	2019-03-26	10-K	19-005573
11	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$4.9M	2017-12-31	2019-03-26	10-K	19-005573
12	net income	us-gaap:NetIncomeLoss	-$8.8M	2025-12-31	2026-03-27	10-K	26-013294
13	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$8.1M	2025-12-31	2026-03-27	10-K	26-013294
14	assets	us-gaap:Assets	$5.1M	2025-12-31	2026-03-27	10-K	26-013294
15	assets	us-gaap:Assets	$3.1M	2024-12-31	2026-03-27	10-K	26-013294
16	current assets	us-gaap:AssetsCurrent	$18.4M	2022-12-31	2024-03-26	10-K	24-011210
17	current liabilities	us-gaap:LiabilitiesCurrent	$4.0M	2022-12-31	2024-03-26	10-K	24-011210
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$79.2M	2022-12-31	2024-03-26	10-K	24-011210
19	operating income	us-gaap:OperatingIncomeLoss	-$27.4M	2022-12-31	2024-03-26	10-K	24-011210
20	book equity	us-gaap:StockholdersEquity	$14.7M	2022-12-31	2025-03-28	10-K	25-001296
21	assets	us-gaap:Assets	$19.6M	2022-12-31	2024-03-26	10-K	24-011210
22	liabilities	us-gaap:Liabilities	$4.0M	2022-12-31	2023-06-09	10-K/A	23-020625
23	total debt	us-gaap:LongTermDebt	$1.9M	2016-12-31	2018-04-02	10-K	18-016275
24	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$1.4M	2016-12-31	2019-03-26	10-K	19-005573
25	operating income	us-gaap:OperatingIncomeLoss	-$5.4M	2016-12-31	2018-04-02	10-K	18-016275
26	depreciation amortization	us-gaap:Depreciation	$1.4M	2016-12-31	2017-04-04	10-K/A	17-000131
27	interest expense	us-gaap:InterestExpense	$5,249	2022-12-31	2023-06-09	10-K/A	23-020625
28	current assets	us-gaap:AssetsCurrent	$4.9M	2025-12-31	2026-03-27	10-K	26-013294
29	current liabilities	us-gaap:LiabilitiesCurrent	$918,400	2025-12-31	2026-03-27	10-K	26-013294
30	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$39.9M	2019-12-31	2020-08-12	10-K/A	20-015385
31	revenue	us-gaap:Revenues	$43.0M	2018-12-31	2020-03-25	10-K	20-006825
32	revenue	us-gaap:Revenues	$48.6M	2017-12-31	2019-03-26	10-K	19-005573
33	revenue	us-gaap:Revenues	$36.1M	2016-12-31	2018-04-02	10-K	18-016275
34	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$5,180	2023-12-31	2025-03-28	10-K	25-001296
35	depreciation amortization	us-gaap:Depreciation	$175,228	2023-12-31	2025-03-28	10-K	25-001296
36	operating income	us-gaap:OperatingIncomeLoss	-$16.4M	2023-12-31	2025-03-28	10-K	25-001296
37	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$17.3M	2023-12-31	2025-03-28	10-K	25-001296
38	income tax	us-gaap:IncomeTaxExpenseBenefit	$28,913	2023-12-31	2025-03-28	10-K	25-001296
39	current assets	us-gaap:AssetsCurrent	$3.6M	2023-12-31	2025-03-28	10-K	25-001296
40	current liabilities	us-gaap:LiabilitiesCurrent	$2.3M	2023-12-31	2025-03-28	10-K	25-001296
41	assets	us-gaap:Assets	$4.3M	2023-12-31	2025-03-28	10-K	25-001296
42	shares outstanding	dei:EntityCommonStockSharesOutstanding	1,887,535	2026-03-24	2026-03-27	10-K	26-013294
43	shares outstanding	dei:EntityCommonStockSharesOutstanding	2,471,656	2025-03-27	2025-03-28	10-K	25-001296

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.